The group's principal activity is to develop drug delivery systems and advanced polymer technology for application in cancer treatment, dermatology and treatment of oral diseases. It is in the development stage. The group has proprietary patents and rights to seven drug delivery technology platforms: synthetic polymer targeted delivery, vitamin mediated targeted delivery (including oral), bioerodible hydrogel technology, nanoparticles and nanoparticle networks, residerm(R) topical delivery, carbohydrate targeting technology and agents for the prevention and treatment of viral disease, including HIV. The products residerm(R) a gel - zindaclin (TM), aphthasol(R) and aptheal(R) are being marketed currently.
